gr 89696 has been researched along with spiradoline in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freeman, J; Grimwood, S; Lu, Y; McLaughlin, JP; McLean, S; Miller, E; Sawant-Basak, A; Schmidt, AW; Vanase-Frawley, MA; Verhoest, PR; Wong, S | 1 |
1 other study(ies) available for gr 89696 and spiradoline
| Article | Year |
|---|---|
Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Topics: Animals; Behavior, Addictive; Biomarkers, Pharmacological; Biphenyl Compounds; Conditioning, Psychological; Depression; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Extinction, Psychological; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Molecular Targeted Therapy; Motor Activity; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Piperazines; Prolactin; Pyrrolidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sulfonamides | 2011 |